Top of this page
Skip navigation, go straight to the content
Since 2015, UCB has embarked on a very important change journey:
the Patient Value Strategy
We are now entering its next phase which we call
“Accelerate & Expand”
We will accelerate our growth potential by maximizing patients’ access to our key medicines, by further improving our ability to demonstrate differentiation and by accelerating the development timelines through new approaches.
The successful evolution of our late stage pipeline requires additional resources in the short-term therefore we will continue to invest significantly into R&D to deliver breakthrough medicines with sustainable value propositions for patients, healthcare professionals and payers and securing UCB sustainability.
Thanks to its strong financial foundations, UCB will selectively use its financial and strategic flexibility to complement its internal pipeline with external innovative assets, programs or platforms through partnerships, licenses or acquisitions.
Continued growth
driven by our key medicines
- Cimzia® growth & expand to non-radiographic axial spondylarthritis patients in the U.S.
- Vimpat® & Briviact® expand to more and more epilepsy patients
- Keppra® & Neupro®
6 potential product launches* by 2025
- Romosozumab in severe osteoporosis (launched in 2019)
- Midazolam nasal spray in acute repetitive epilepsy seizures (launched in 2019)
- Bimekizumab in psoriasis, psoriatic arthritis, axial spondyloarthritis
- Rozanolixizumab in Immune ThrombocytoPenia, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy
- Padsevonil in drug-resistant epilepsy
- Anti-Tau in progressive supranuclear palsy
* subject to approval
Our key medicines
We bring solutions to people living with neurological or immunological diseases.
In these areas, we have 5 main medicines on the market.
Immunology
Peak sales guidance
- Neupro® ~ 2018 level
- Vimpat® > € 1.4 billion by 2022
- Cimzia® > € 1.7 billion by 2024
- Briviact® > € 600 million by 2026
Our pipeline
In a challenging environment, our pipeline builds the basis of UCB’s sustainable long term growth.
To create a pipeline that will make a real difference in people’s lives, we focus on our key assets: our expertise in small and large molecules and our expertise in the fields of neurology and auto-immune diseases.
6 potential product launches* by 2025
- Romosozumab in severe osteoporosis (launched in 2019)
- Midazolam nasal spray in acute repetitive epilepsy seizures (launched in 2019)
- Bimekizumab in psoriasis, psoriatic arthritis, axial spondyloarthritis
- Rozanolixizumab in Immune ThrombocytoPenia, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy
- Padsevonil in drug-resistant epilepsy
- Anti-Tau in progressive supranuclear palsy
* subject to approval
Clinical studies index
UCB is committed to sharing information on studies and making study results publicly accessible. You will find below links to the clinical studies (Phase 2-4) of our main R&D projects.
More information about our clinical studies index and our position paper are available here.
July 2019
CIDP: Chronic Inflammatory Demyelinating Polyneuropathy
Changes since July 2019:
- UCB0107: Phase 1 results (September 2019)
- Evenity™ (romosozumab): CHMP positive opinion (October 2019) & EU approval (December 2019)
- bimekizumab: first positive Phase 3 trial (BE VIVID - versus placebo and ustekinumab) in psoriasis (October 2019)
- bimekizumab: second positive Phase 3 trial (BE READY - versus placebo) in psoriasis (November 2019)
- bimekizumab: third positive Phase 3 trial (BE SURE - versus adalimumab) in psoriasis (December 2019)
- Nayzilam® (midazolam): launch in the U.S. (December 2019)